Advanced search
Publication Cover
Future Cardiology Volume 4, 2008 - Issue 1
Submit an article Journal homepage
159
Views
0
CrossRef citations to date
0
Altmetric
Review

Appetite for Destruction: E3 Ubiquitin-Ligase Protection in Cardiac Disease

Monte S Willisa University of North Carolina Department of Pathology & Laboratory Medicine Carolina Cardiovascular Biology Center2340B Medical Biomolecular Research BuildingChapel HillNC27599–7525USA. Tel: +1 919 843 1938; Fax: +1 919 843 4585; [email protected]
,
Jonathan C Schislerb University of North Carolina Division of Cardiology & Carolina Cardiovascular Biology Center8200 Medical Biomolecular Research BuildingChapel HillNC27599–7126USA. Tel: +1 919 843 2757; Fax: +1 919 843 4585;[email protected]
&
Cam Pattersonc University of North Carolina Division of Cardiology & Carolina Cardiovascular Biology Center8200 Medical Biomolecular Research BuildingChapel HillNC27599–7126USA. Tel: +1 919 843 6477; Fax: +1 919 843 4585;[email protected]
Pages 65-75 | Published online: 18 Dec 2007

Bibliography

  • Goldberg AL : Protein degradation and protection against misfolded or damaged proteins.Nature, 426, 895–899 (2003).
  • Bao J , SatoK, LiMet al.: PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IκBα degradation. Am. J. Physiol. Heart Circ. Physiol., 281, H2612–H2618 (2001).
  • Gao Y , LeckerS, PostMJet al.: Inhibition of ubiquitin-proteasome pathway-mediated IκBα degradation by a naturally occurring antibacterial peptide. J. Clin. Invest., 106, 439–448 (2000).
  • Luss H , SchmitzW, NeumannJ: A proteasome inhibitor confers cardioprotection.Cardiovasc. Res., 54, 140–151 (2002).
  • Pye J , ArdeshirpourF, McCainAet al.: Proteasome inhibition ablates activation of NF-κB in myocardial reperfusion and reduces reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 284, H919–H926 (2003).
  • Stangl K , GüntherC, FrankTet al.: Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochem. Biophys. Res. Commun., 291, 542–549 (2002).
  • Stansfield WE , MossNC, WillisMS, Tang R, Selzman CH: Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann. Thorac. Surg., 84, 120–125 (2007).
  • Johnson SA , HunterT: Kinomics: methods for deciphering the kinome.Nat. Methods, 2, 17–25 (2005).
  • Wilkinson KD , VentiiKH, FriedrichKL, MullallyJE: The ubiquitin signal: assembly, recognition and termination. Symposium on ubiquitin and signaling.EMBO Rep., 6, 815–820 (2005).
  • Coleman PS , ParmacekMS, LeschM, SamarelAM: Protein synthesis and degradation during regression of thyroxine-induced cardiac hypertrophy.J. Mol. Cell Cardiol., 21, 911–925 (1989).
  • Parmacek MS , MagidNM, LeschM, DeckerRS, SamarelAM: Cardiac protein synthesis and degradation during thyroxine-induced left ventricular hypertrophy.Am. J. Physiol., 251, C727–C736 (1986).
  • Razeghi P , BaskinKK, SharmaSet al.: Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. Biochem. Biophys. Res. Commun., 342, 361–364 (2006).
  • Adams V , LinkeA, WisloffUet al.: Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc. Res., 73, 120–129 (2007).
  • Li HH , KedarV, ZhangCet al.: Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest., 114, 1058–1071 (2004).
  • Frey N , OlsonEN: Cardiac hypertrophy: the good, the bad, and the ugly.Annu. Rev. Physiol., 65, 45–79 (2003).
  • Ni YG , BerenjiK, WangNet al.: Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation, 114, 1159–1168 (2006).
  • Li HH , WillisMS, LockyerPet al.: Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J. Clin. Invest., 117, 3211–3223 (2007).
  • Deng L , WangC, SpencerEet al.: Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell, 103, 351–361 (2000).
  • Spence J , SadisS, HaasAL, FinleyDA: Ubiquitin mutant with specific defects in DNA repair and multiubiquitination.Mol. Cell Biol., 15, 1265–1273 (1995).
  • Hoshijima M : Mechanical stress- strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures.Am. J. Physiol. Heart Circ. Physiol., 290, H1313–H1325 (2006).
  • Centner T , YanoJ, KimuraEet al.: Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J. Mol. Biol., 306, 717–726 (2001).
  • Gregorio CC , PerryCN, McElhinnyAS: Functional properties of the titin/connectin-associated proteins, the muscle-specific RING finger proteins (MURFs), in striated muscle.J. Muscle Res. Cell. Motil., 26, 389–400 (2005).
  • Mrosek M , LabeitD, WittSet al.: Molecular determinants for the recruitment of the ubiquitin-ligase MuRF-1 onto M-line titin. FASEB J., 21, 1383–1392 (2007).
  • Arya R , KedarV, HwangJRet al.: Muscle ring finger protein-1 inhibits PKCε activation and prevents cardiomyocyte hypertrophy. J. Cell Biol., 167, 1147–1159 (2004).
  • Kedar V , McDonoughH, AryaRet al.: Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc. Natl Acad. Sci. USA, 101, 18135–18140 (2004).
  • Willis MS , IkeC, LiLet al.: Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circulation Res., 100, 456–459 (2007).
  • Lange S , ViholaA, UddB: The kinase domain of titin controls muscle gene expression and protein turnover.Science, 308, 1599–1603 (2005).
  • Zhang C , XuZ, HeXR, MichaelLH, PattersonC: CHIP, a cochaperone/ubiquitin ligase that regulates protein quality control, is required for maximal cardioprotection after myocardial infarction in mice.Am. J. Physiol. Heart Circ. Physiol., 288, H2836–H2842 (2005).
  • Tripathi V , AliA, BhatR, PatiU: CHIP chaperones wild type p53 tumor suppressor protein.J. Biol. Chem., 282, 28441–28454 (2007).
  • Haupt Y , MayaR, KazazA, OrenM: Mdm2 promotes the rapid degradation of p53.Nature, 387, 296–299 (1997).
  • Kubbutat MH , JonesSN, VousdenKH: Regulation of p53 stability by Mdm2.Nature, 387, 299–303 (1997).
  • Momand J , ZambettiGP, OlsonDC, GeorgeD, LevineAJ: The Mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.Cell, 69, 1237–1245 (1992).
  • Toth A , NicksonP, QinLL, ErhardtP: Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase.J. Biol. Chem., 281, 3679–3689 (2006).
  • Foo RS , ChanLK, KitsisRN, BennettMR: Ubiquitination and degradation of the anti-apoptotic protein ARC by MDM2.J. Biol. Chem., 282, 5529–5535 (2007).
  • Xiong S , Van Pelt CS, Elizondo-Fraire AC, Fernandez-Garcia B, Lozano G: Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation, 115, 2925–2930 (2007).
  • Spencer JA , EliazerS, IlariaRL Jr, Richardson JA, Olson EN: Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein. J. Cell Biol., 150, 771–784 (2000).
  • Fielitz J et al. , van Rooij E, Spencer JA : Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction. Proc. Natl Acad. Sci. USA, 104, 4377–4382 (2007).
  • Fielitz J , KimMS, SheltonJMet al.: Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J. Clin. Invest., 117, 2486–2495 (2007).
  • Holschermann H , SchusterD, ParvizB, HaberboschW, TillmannsH, MuthH: Statins prevent NF-κB transactivation independently of the IKK-pathway in human endothelial cells.Atherosclerosis, 185, 240–245 (2006).
  • Ross AM , GibbonsRJ, StoneGW, Kloner RA, Alexander RW: A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol., 45, 1775–1780 (2005).
  • Yoo CG , LeeS, LeeCT, KimYW, HanSK, ShimYS: Effect of acetylsalicylic acid on endogenous IκB kinase activity in lung epithelial cells.Am. J. Physiol. Lung Cell Mol. Physiol., 280, L3–L9 (2001).
  • Di Napoli M , PapaF: MLN-519. Millennium/PAION.Curr. Opin Investig. Drugs, 4, 333–341 (2003).
  • Bross PF , KaneR, FarrellATet al.: Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res., 10, 3954–3964 (2004).
  • Richardson PG , SonneveldP, SchusterMWet al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med., 352, 2487–2498 (2005).
  • Enrico O , GabrieleB, NadiaCet al.: Unexpected cardiotoxicity in haematological bortezomib treated patients. Br. J. Haematol., 138, 396–397 (2007).
  • Berenson JR , MatousJ, SwiftRA, Mapes R, Morrison B, Yeh HS: A Phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin. Cancer Res., 13, 1762–1768 (2007).
  • Meiners S , LauleM, RotherWet al.: Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation, 105, 483–489 (2002).
  • Stangl V , LorenzM, MeinersSet al.: Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J., 18, 272–279 (2004).
  • Herrmann J , SagunerAM, VersariDet al.: Chronic proteasome inhibition contributes to coronary atherosclerosis. Circulation Res., 101(9), 865–874 (2007).
  • Wang X , RobbinsJ: Heart failure and protein quality control.Circulation Res., 99, 1315–1328 (2006).
  • Maron BJ : Triggers for sudden cardiac death in the athlete.Cardiol. Clin., 14, 195–210 (1996).
  • Bonne G , CarrierL, RichardP, HainqueB, SchwartzK: Familial hypertrophic cardiomyopathy: from mutations to functional defects.Circulation Res., 83, 580–593 (1998).
  • Richard P , CharronP, CarrierLet al.: Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation, 107, 2227–2232 (2003).
  • Flavigny J , RobertP, CamelinJC, Schwartz K, Carrier L, Berrebi-Bertrand I: Biomolecular interactions between human recombinant β-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy. Cardiovasc. Res., 60, 388–396 (2003).
  • Freiburg A , GautelM: A molecular map of the interactions between titin and myosin-binding protein C: implications for sarcomeric assembly in familial hypertrophic cardiomyopathy.Eur. J. Biochem., 235, 317–323 (1996).
  • Gruen M , GautelM: Mutations in β-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C.J. Mol. Biol., 286, 933–949 (1999).
  • Squire JM , LutherPK, KnuppC: Structural evidence for the interaction of C-protein (MyBP-C) with actin and sequence identification of a possible actin-binding domain.J. Mol. Biol., 331, 713–724 (2003).
  • Sarikas A , CarrierL, SchenkeCet al.: Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc. Res., 66, 33–44 (2005).
  • Moolman JA , ReithS, UhlKet al.: A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation, 101, 1396–1402 (2000).
  • Rottbauer W , GautelM, ZeheleinJet al.: Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization of cardiac transcript and protein. J. Clin. Invest., 100, 475–482 (1997).
  • Flavigny J , SouchetM, SébillonPet al.: COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes. J. Mol. Biol., 294, 443–456 (1999).
  • Yang Q , SanbeA, OsinskaH, HewettTE, KlevitskyR, RobbinsJ: In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy.Circulation Res., 85, 841–847 (1999).
  • Lindsten K et al. , de Vrij FM, Verhoef LG : Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell Biol., 157, 417–427 (2002).
  • Kim HT , KimKP, LlediasFet al.: Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J. Biol. Chem., 282, 17375–17386 (2007).
  • Hall G , HasdayJD, RogersTB: Regulating the regulator: NF-κB signaling in heart.J. Mol. Cell Cardiol., 41, 580–591 (2006).
  • Kopp EB , GhoshS: NF-κB and rel proteins in innate immunity.Adv. Immunol., 58, 1–27 (1995).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.